b-cell lymphoblastic leukemia is a serious hematopoietic malignancy that is highly malignant, metastasizes rapidly, and has a rapid onset of disease. B-lymphoblastic leukemia is a clonal hematopoietic stem cell tumor derived from B-cell progenitor cells. patients with b-lymphoblastic leukemia usually present with severe anemia, thrombocytopenia, and a significant decrease in neutrophil count due to abnormal hematopoiesis caused by the tumor cells occupying the normal bone marrow space and crowding out the bone marrow cells. Symptoms include frequent infections, fever, easy bruising, difficulty stopping bleeding, and flat, dark red spots (petechiae) caused by bleeding under the skin. Currently, the treatment regimen consists of early intensive therapy with high-dose anthracycline-based chemicals, such as adriamycin phosphoramidite, vincristine, and dexamethasone alternated with high-dose methotrexate and cytarabine, and maintenance therapy and adjuvant therapy with hematopoietic stem cell transplantation after a complete remission has been achieved. It is recommended to go to the hospital for diagnosis and treatment when symptoms of lymphoblastic leukemia appear, so as to avoid delaying the condition. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.